{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:28Z","timestamp":1779217048593,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"DOI":"10.7759\/cureus.105830","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:57:22Z","timestamp":1774447042000},"source":"Crossref","is-referenced-by-count":1,"title":["Statin-Associated Immune-Mediated Necrotizing Myopathy: An Underrecognised Cause of Progressive Muscle Weakness in Primary Care"],"prefix":"10.7759","author":[{"given":"Jee Tat","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teh Rohaila","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Say Yee","family":"Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2022.18.2.89","article-title":"Statin-related muscle toxicity: an evidence-based review","volume":"18","author":"Jeeyavudeen MS","year":"2022","unstructured":"Jeeyavudeen MS, Pappachan JM, Arunagirinathan G. Statin-related muscle toxicity: an evidence-based review. touchREV Endocrinol. 2022, 18:89-95. 10.17925\/EE.2022.18.2.89","journal-title":"touchREV Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen AL","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016, 374:664-9. 10.1056\/NEJMra1515161","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach Y","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018, 28:87-99. 10.1016\/j.nmd.2017.09.016","journal-title":"Neuromuscul Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-025-00481-2","article-title":"Trends in reports of statin-associated immune-mediated necrotizing myopathy using the Japanese Adverse Drug Event Report database","volume":"12","author":"Takami A","year":"2025","unstructured":"Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A. Trends in reports of statin-associated immune-mediated necrotizing myopathy using the Japanese Adverse Drug Event Report database. Drugs Real World Outcomes. 2025, 12:145-52. 10.1007\/s40801-025-00481-2","journal-title":"Drugs Real World Outcomes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes ES","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al.. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015, 36:1012-22. 10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000497","article-title":"Statin-associated autoimmune myopathy: a systematic review of 100 cases","volume":"23","author":"Nazir S","year":"2017","unstructured":"Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017, 23:149-54. 10.1097\/RHU.0000000000000497","journal-title":"J Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018, 20:21. 10.1007\/s11926-018-0732-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","article-title":"Immune-mediated necrotizing myopathy in a multi-ethnic Malaysian cohort","volume":"26","author":"Tan CY","year":"2021","unstructured":"Tan CY, Ambang T, Raja J, et al.. Immune-mediated necrotizing myopathy in a multi-ethnic Malaysian cohort. Neurol Asia. 2021, 26:291-9.","journal-title":"Neurol Asia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson RS","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M, et al.. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017, 70:1290-301. 10.1016\/j.jacc.2017.07.752","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71633-7","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis","volume":"14","author":"Onchan T","year":"2024","unstructured":"Onchan T, Foocharoen C, Pongkulkiat P, Suwannaroj S, Mahakkanukrauh A. Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis. Sci Rep. 2024, 14:20646. 10.1038\/s41598-024-71633-7","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik A","year":"2016","unstructured":"Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol. 2016, 7:64. 10.3389\/fneur.2016.00064","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474137-statin-associated-immune-mediated-necrotizing-myopathy-an-underrecognised-cause-of-progressive-muscle-weakness-in-primary-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:57:22Z","timestamp":1774447042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474137-statin-associated-immune-mediated-necrotizing-myopathy-an-underrecognised-cause-of-progressive-muscle-weakness-in-primary-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.105830","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}